{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-030856","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.760664+00:00","generated_at":"2026-06-13T19:04:57.220439+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant reports positive chronic data for RVT-3101 in ulcerative colitis, efficacy improved from induction at week 56","bullets":["At expected Phase 3 dose, Clinical Remission 36% at week 56 vs 29% at week 14; Endoscopic Improvement 50% vs 36%.","In biomarker-positive patients, Clinical Remission 43% at week 56 (33% at week 14), Endoscopic Improvement 64% (47%).","Favorable safety profile through 56 weeks; 0% neutralizing antibodies at week 56 at Phase 3 dose.","First long-duration data for an anti-TL1A antibody; results support Phase 3 potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-030856","json":"https://secwatch.observer/filing/0001140361-23-030856.json","markdown":"https://secwatch.observer/filing/0001140361-23-030856.md","text":"https://secwatch.observer/filing/0001140361-23-030856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123030856/0001140361-23-030856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123030856/brhc20054731_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:04:57.220439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}